

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) A composition comprising an antigen, a saponin adjuvant, and an excipient, wherein the composition reduces the *in vitro* lytic effect of the saponin adjuvant.
2. (original) The composition according to claim 1, wherein the saponin adjuvant is a substantially pure saponin adjuvant.
3. (original) The composition according to claim 2, wherein the substantially pure saponin adjuvant is QS-7 or QS-21.
4. (original) The composition according to claim 1, wherein the saponin adjuvant is a heterogenous saponin adjuvant.
5. (original) The composition according to claim 4, wherein the heterogeneous saponin adjuvant is Quil A.
6. (original) The composition according to claim 1, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid encoding the peptide or protein.
7. (original) The composition according to claim 1, wherein the excipient is a nonionic surfactant.
8. (original) The composition according to claim 7, wherein the nonionic surfactant is a Polysorbate.
9. (original) The composition according to claim 8, wherein the Polysorbate is Polysorbate 20, Polysorbate 40, Polysorbate 60, or Polysorbate 80.
10. (original) The composition according to claim 1, wherein the excipient is a cyclodextrin.
11. (original) The composition according to claim 10, wherein the cyclodextrin is β - cyclodextrin.

12. (original) The composition according to claim 11, wherein the β - cyclodextrin hydroxypropyl- β - cyclodextrin.

13. (original) The composition according to claim 1, wherein the composition further maintains the maximum adjuvant activity of QS-21.

14. (original) The composition according to claim 13, wherein the saponin adjuvant is a substantially pure saponin adjuvant.

15. (original) The composition according to claim 14, wherein the substantially pure saponin adjuvant is QS-7 or QS21.

16. (original) The composition according to claim 13, wherein the saponin adjuvant is a heterogenous saponin adjuvant.

17. (original) The composition according to claim 16, wherein the heterogeneous saponin adjuvant is Quil A.

18. (original) The composition according to claim 13, wherein the antigen is a peptide, a protein, a polysaccharide, a lipid, or a nucleic acid encoding the peptide or protein.

19. (original) The composition according to claim 13, wherein the excipient is a nonionic surfactant

20. (original) The composition according to claim 19, wherein the nonionic surfactant is a Polysorbate.

21.-45. (canceled)